Cell death pathway implicated in bone marrow failure

Vanderbilt investigators have linked a specific form of programmed cell death to myelodysplastic syndrome, a type of bone marrow failure.

Teamwork key to treating patient’s rare blood cancer

Former sports journalist Joe Lofaro has little memory of Oct. 23, 2015, when his son Daniel loaded him into a car at his Martin, Tennessee, home and said, ‘Come on, Dad, we’re going for a ride.”

Connecting an asthma gene to leukemia

A receptor previously implicated in asthma may also play roles in other allergic diseases and in leukemia, Vanderbilt researchers have discovered.

News Around the Cancer Center

Vanderbilt-Ingram Cancer Center patients treated with new FDA-approved CAR-T therapy

Vanderbilt-Ingram Cancer Center has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR-T) therapy for treatment of adult patients with a specific type of lymphoma. VICC is the only cancer center in a seven-state region of the Southeast authorized to deliver the new immunotherapy.

New cutting-edge treatment for type of pediatric leukemia offered at Monroe Carell Jr. Children’s Hospital at Vanderbilt